C12orf45

Across TCGA pan-cancer cohorts, C12orf45 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C12orf45 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher C12orf45 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C12orf45 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where C12orf45 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.595	0.281	.001	79	view →
CCRCC	OS	Median	III,IV	0.770	1.000	.004	23	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.655	.003	17	view →
LUAD	OS	Median	II,III,IV	0.815	0.491	.006	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C12orf45–PDAC (DFS)

Open the PDAC breakdown →